



103218-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Ilse Zolle, et al  
SERIAL NO. : 10/635,294  
FILED : August 6, 2003  
FOR : **Radiolabelled Phenylethyl Imidazole Caboxylic Acid  
Ester Derivatives**  
ART UNIT : To Be Assigned  
EXAMINER : To Be Assigned

---

January 9, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.


This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

Copies of all references listed on the attached Form PTO-1449 are being supplied.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

By   
Theodore A. Gottlieb  
Reg. No. 42,597

220 East 42<sup>nd</sup> Street  
30<sup>th</sup> Floor  
New York, New York 10017  
(212) 808-0700


CERTIFICATE OF EXPRESS MAILING

I hereby certify that the foregoing Information Disclosure Statement and the accompanying Form PTO-1449 (1 Sheet) is being deposited with the United States Postal Service as express mail Express Mail Label No. EV383033872 US in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date indicated below:

Date: 11/9/04

By   
Agata Glinska

<b>LIST OF PATENTS AND PUBLICATIONS</b> <b>APPLICANT'S INFORMATION</b> <b>DISCLOSURE STATEMENT</b> (Form PTO-1449)				Attorney Docket: 103218-1		Serial No.: 10/635,294	
				Applicant: Ilsa Zolle et al.			
				Filing Date: August 6, 2003		Group: To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner		Document Number	Date	Name	Class	Sub Class	Filing Date If appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub Class	Translation Yes N
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	A	Beierwaltes W. H., Wieland D. M., Ice R. D., Seabold J.E., Sarkar S. D., Gill S. P., and Mosley S. T.: Localization of radiolabeled enzyme inhibitors in the adrenal gland. J. Nucl. Med., 17(11), 998-1002, 1976.					
	B	Napoli J.L., Counsel R.E.: New inhibitors of steroid 11 $\beta$ -hydroxylase. Structure-activity relationship studies of metyrapone-like compounds. J. Med. Chem., 20, 762-766 (1997).					
	C	Beierwaltes W. H., Wieland D. M., Mosley S. T., Swanson D.P., Sarkar S.D., Freitas J.E., Thrall J.H. and Herwig K.R.: Imaging the adrenal glands with radiolabeled inhibitors of enzymes: concise communication. J. Nucl. Med., 19(2), 200-203, 1978.					
	D	Beierwaltes W.H., Wieland D.M., Yu T., Swanson D.P., Mosley S.T.: Adrenal Imaging Agents: Rationale, Synthesis, Formulation and, Metabolism. Semin. Nucl. Med., 8: No. 1: 5-21, 1978					
	E	Robien W. And Zolle I. (1983) Synthesis of radioiodinated metyrapone-A potential agent for functional imaging of the adrenal cortex. Int. J. Appl. Radiat. Isot. 34: 907-914.					
	F	Zolle I., Woloszczuk W., and Hofer R.: Synthesis and in vitro evaluation of metyrapone derivatives as potential inhibitors of 11 $\beta$ -hydroxylase activity. In: Radiopharmaceuticals and labeled compounds, 337-342, IAEA-CN-45/67, Vienna, 1985.					
	G	Vanden Bossche H., Willemsens G., Cools W., Bellens D. (1984) Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals. Biochemical Pharmacology: 33(23), 3861-3868					
	H	Engelhardt D (1994) Steroid biosynthesis inhibitors in Cushing's syndrome. Clin Investig 72: 481-488.					
	I	Wagner R.L., White P.F., Kan P.B., Rosenthal M.H., Feldman d. (1984) Inhibition of adrenal steroidogenesis by the anesthetic etomidate. New England J.Medicine: 310(22): 1415-1421.					
	J	Godefroi, E.F., Janssen, P.A.J., Van der Eycken, C.A.M., Van Heertum, A.H.M.T., Niemegeers, C.J.E. (1965) DL-1-(1-Arylalkyl)imidazole-5-carboxylate esters. A novel type of hypnotic agents. J. Med. Chem. 8: 220-223.					
	K	Yu, J., Zolle, I., Mertens, J., and Rakias, F.: Synthesis of 2-(131)-iodophenyl-metyrapone using Cu(I)-assisted nucleophilic exchange labelling: Study of the reaction conditions. Nucl. Med. & Biol. 22(2):257-262 (1995).					
	L	De Coster R., Degryse A.-D., Van Dijk P., Ooms L.A.A., Lagerweij E. (1987) Comparison of the effects of etomidate and its fluoro analogue, r 8110, on plasma cortisol, 11 $\beta$ -deoxycortisol, 17 $\alpha$ -hydroxyprogesterone and testosterone concentrations in dogs. J. vet. Pharmacol. Therap. 10: 227-232					
	M	Berström M, Bonasera TA, Lu L, Bergström E, Backlin C, Juhlin C, Langström B (1998) In vitro and in vivo primate evaluation of carbon-11- etomidate and carbon -11-metomidate as a potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 39: 982-989.					
	N	Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, Langerström B, (2000) PET imaging of adrenal cortical tumors with the 11b- hydroxylase tracer <sup>11</sup> C- metomidate. J Nucl Med 41:					



	275-282.		
	Khan T. S., Sundin A, Juhlin C., Langertröm B., Bergström M., Eriksson B. (2003) $^{11}\text{C}$ - metomidate PET imaging of adrenocortical cancer. <i>Eur. J. Med. &amp; Molec. Imaging</i> Vol. 30: 403-410		
P	Reincke M, Fassnacht M, Väh S, Mora P, Allolio B (1996) Adrenal incidentalomas: A manifestation of the metabolic syndrome. <i>Endocrine Research</i> 22 (4): 757-761.		
Q	Herrera MF, Grant CS, van Heerden JA, et al. (1991) Incidentally discovered adrenal tumors: an institutional perspective. <i>Surgery</i> 110: 1014-1021.		
R	Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B, (1995) Incidentally discovered adrenal masses. <i>Endocrin Rev.</i> 16: 460-484.		
S	Mantero F., Terzolo M., Arnaldi G., Osella G., Masini A.M., Ali A., Giovagnetti M., Opocher G., Angeli A. (2000) A survey on adrenal incidentaloma in Italy. <i>J. Endocrinol. &amp; Metab.</i> 85(2): 637-644		
T	Mitsunobu O. (1981) <i>Synthesis</i> : 1-28. Hughes D. L. (1992) <i>Org. Reactions</i> 42: 335-656.		
U	Hughes D. L. (1996) <i>Org Prep Proced. Int.</i> 28: 127-164.		
V	Merkushev E. B. (1988) <i>Synthesis</i> : 923- 937		
W	Ali H. and van Lier J. E. (1996) <i>Synthesis</i> : 423-445.		
X	Baldwin R.M., Zea-Ponce Y., Zoghbi S.S., Lauelle M., Al-Tikriti M.S., Sybirska E.H. Malison R.T., Neumeyer J.L., Milius R.A., Wang S., Stabin M., Smith E.O., Charney D.S., Hoffer P.B., and Innis RB., (1993) Evaluation of the monoamine uptake site ligand [ $^{123}\text{I}$ ] methyl -3 $\beta$ -(4-iodophenyl)- tropane-2 $\beta$ -carboxylate( [ $^{123}\text{I}$ ] $\beta$ -CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. <i>Nucl. Med. Biol.</i> 20: 597-606.		
Y	Laumen K. and Schneider M.P. (1988) <i>J. Chem. Soc. Chem. Comm.</i> : 598-600.		
Z	Botta M., Summa V., Trapassi G., Monteagudo E., Corelli F., (1994) <i>Tetrahedron: Asymmetry</i> 5: 181-184.		
AA	Corelli F., Summa V., Brogi A., Monteagudo E., Botta M., (1995) <i>J. Org. Chem.</i> 60: 2008-2015.		
<table border="1" style="width: 100%;"> <tr> <td style="width: 50%;"><b>EXAMINER:</b></td> <td style="width: 50%;"><b>DATE CONSIDERED:</b></td> </tr> </table>		<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>
<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>		
<ul style="list-style-type: none"> <li><b>EXAMINER:</b> Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.</li> </ul>			